Subject
Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health
Reference16 articles.
1. Patients eligible for modulator drugs: data from cystic fibrosis registry of Turkey;Çobanoğlu;Pediatr Pulmonol,2020
2. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation;De Boeck;J Cyst Fibros Off J Eur Cyst Fibros Soc,2014
3. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study;Davies;Lancet Respir Med,2016
4. Ivacaftor treatment of cystic fibrosis in children aged 12 to < 24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study;Rosenfeld;Lancet Respir Med,2018
5. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study;McNamara;Lancet Respir Med,2019
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献